Ipriflavone is a synthetic flavonoid (isoflavone) derived from the soy compound daidzein. Ipriflavone is an anabolic isoflavone, i.e. it builds muscle and bone. Unlike other soy isoflavones, it has no estrogenic or other hormonal activity. The anabolic activity of this compound has been compared to such anabolic steroids as oxandrolone, stanazolol, or methenolone, but it is vastly safer and has no side effects. Ipriflavone also increases endurance.
Ipriflavone has created a lot of excitement as a treatment for osteoporosis. It increases bone density by increasing the uptake of phosphorus and calcium
in the bone by stimulating bone building osteoblasts and enhancing calcitonin while inhibiting osteoclasts which break-down bone tissue.
Ipriflavone can also decreases cholesterol and lowers bad LDL cholesterol while increasing good HDL cholesterol.
Halting Bone Loss:
Ipriflavone is a registered treatment for osteoporosis in many European countries and Japan. It is used as an alternative to hormone treatments for increasing bone mass and relieving the pain of osteoporosis. It’s often used in conjunction with low dosages of estrogen to increase their anti-osteoporotic effects. The research has also demonstrated that ipriflavone appears to produce its strongest bone-building actions when given in conjunction with other bone-supporting supplements.
Prevents Bone Loss and Fractures:
Even though the discovery of ipriflavone dates back to the 1930s, it was not produced in the laboratory until the 1970s. Animal studies, which began in 1974, led to human studies being conducted in 1981. During the 1980s and 1990s a number of randomized, double-blind, placebo controlled studies demonstrated ipriflavone could prevent or decrease the loss of bone mass in postmenopausal women.
Research studies have shown that taking a daily dose of 600 mg of ipriflavone could increase bone density by as much as 9% in three to nine months and cause a significant reduction of fractures after two years of treatment. Since then, close to 500 patients treated with ipriflavone in double-blind, placebo controlled studies have noted significant gains of between .5 to 7.1 percent in total body, forearm and vertebral bone mineral density. Ipriflavone has also resulted in the relief of pain and an increase in mobility.
Structure and Function Similar With Estrogen:
Researchers have shown that chemical structure of ipriflavone is similar to the structure of estrogen. That explains why it mimics the action of estrogen on preventing bone loss. Estrogens inhibit bone-degrading osteoclast activity that causes bone resorption and ipriflavone protects bone in a similar manner.
Despite the ability of ipriflavone to augment the activity of naturally occurring or administered estrogens, ipriflavone does not have any estrogenic effects on the hypothalamus and pituitary gland. It does not have the estrogenic actions of stimulating breast and uterine tissue either. These estrogenic actions may be dangerous for postmenopausal women who are genetically prone to female cancers. Ipriflavone simply improves the structure of bone and prevents the loss of bone without any harmful side effects.
Stronger Actions Than Calcitonin:
Researchers have compared the bone restoring effects of ipriflavone with the FDA-approved osteoporosis treatment hormone Calcitonin. The study found that ipriflavone had a greater ability to inhibit the formation of osteoclasts and bone resorption, while simultaneously stimulating the formation of osteoblasts to form new bone cells. Unlike calcitonin, ipriflavone was found to be free of serious side effects.
Builds New Bone:
Research shows that ipriflavone activates osteoblasts. When osteoblasts are exposed to ipriflavone and its metabolites, the cellular process of manufacturing bone-matrix proteins and bone-mineral deposition is stimulated.
Clinical human trials have demonstrated significant increase of bone density from ipriflavone treatment.(18,19) Furthermore, the research indicates that the bone-building actions of ipriflavone are more pronounced when ipriflavone is administered in conjunction with several other bone-support nutrients:
3) vitamin K.
Ipriflavone and Calcium
Ipriflavone has been shown to work with calcium supplements to help maintain stronger bones. Ipriflavone improves calcium metabolism in bone by fusing itself to specific binding sites in precursor cells and mature osteoclasts, the cells that digest bone. As a result, ipriflavone alters bone calcium flux and inhibits bone resorption.
One two-year study evaluated ipriflavone’s spinal bone-building effects in postmenopausal women with low vertebral bone density. These women took either 200 mg of ipriflavone, three times daily along with 1 gram of calcium, or only calcium and a placebo. Following six months of ipriflavone-calcium supplementation, spinal bone density increased 1.4 percent, a clinically significant amount, In the control group taking the placebo, bone density decreased overall by 1.2 percent after two years.
Additionally, twenty women enrolled in the placebo group who had recently become menopausal experienced a 4.9% decrease in bone density after the second year. This is most likely explained by the fact that the most rapid loss of bone occurs within the first five years of menopause.
Another group of scientists examined the ability of ipriflavone to prevent bone loss occurring shortly after menopause. Fifty-six postmenopausal women with low vertebral bone density received either 200 mg of ipriflavone three times daily or a placebo. All subjects also received 1,000 mg of elemental calcium daily.
After two years researchers noted that there was no loss in vertebral bone density in the women receiving both ipriflavone and calcium, while women taking only calcium experienced a 4.9% loss in bone density.
The most effective form of calcium to use with ipriflavone appears to be Microcrystalline Hydroxyapatite (MCHC). MCHC is an extract of whole bone that contains calcium, magnesium, zinc, silica, manganese, and many other trace minerals in their natural ratios, as well as residues of matrix, proteins, and glycosaminoglycans.
MCHC is the only form of calcium that has been shown to reconstruct bone and restore bone loss when taken as a supplement. This makes MCHC the ideal companion supplement to ipriflavone. In a study of osteoporotic postmenopausal women with the complication of primary biliary cirrhosis, MCHC not only reduced bone loss but it actually increased cortical bone thickness.
Those taking MCHC showed a 6.1% increase in bone thickness. Conversely, calcium gluconate halted the bone loss but did not restore it, and the group receiving no supplementation continued to show accelerated loss of bone. Other studies show that MCHC has a higher level of absorption and greater bioavailability than either calcium gluconate or calcium carbonate.
MCHC has other proven benefits on bone formation. Elderly subjects taking MCHC experienced more rapid healing of fractures when compared to the rate of healing in subjects who did not take MCHC. MCHC has also been shown to dramatically reduce bone loss in surgically induced postmenopausal women, and MCHC has been called a valuable therapy in preventing osteoporosis in individuals with rheumatoid arthritis.
Vitamin D and Ipriflavone:
Vitamin D and its metabolites stimulate the absorption of calcium from the gut and the resorption of calcium in bone. In fact, a deficiency of vitamin D and a failure to metabolize vitamin D in the liver are known factors in the development of osteoporosis. Ipriflavone and vitamin D have been found to work synergistically to increase bone mineral density. In research studies, a combination of vitamin D3 and ipriflavone have shown superior bone building actions when compared to taking ipriflavone alone. The combination regimen increased bone mineral density over the entire length of the femur while the administration of Vitamin
D3 alone had no effect.
An 18-month study found that the combined regimen of ipriflavone and vitamin D3 was effective in stopping postmenopausal bone loss. The mean bone loss of the combined regimen group was .33% versus 2.37% for the ipriflavone alone group, 1.15% for the vitamin D3 alone group and and 3.70% for the control group. The synergistic actions of ipriflavone and vitamin D regimen may be the result of a direct effect of each agent on osteoblastic (bone forming) cells.
Vitamin K and Ipriflavone:
Ipriflavone and vitamin K’s actions on bone metabolism are complementary. Vitamin K is needed to convert the inactive portion of the bone protein osteocalcin to the active form that anchors calcium in bone. Vitamin K also inhibits the resorptive actions of mature osteoclasts while halting the formation of new osteoclasts.
Researchers have demonstrated that the inhibitory effects of vitamin K on bone resorption are similar to those of ipriflavone but operate through different mechanisms. As a result the combination of vitamin K and ipriflavone has additive actions in preventing bone resorption.
Maximum Bone Building Support with Ipriflavone Complex For maximum benefits on rebuilding strong bones and in preventing osteoporosis, a combination regimen of ipriflavone with vitamin D , calcium MCHP, vitamin K and other bone-support agents that includes magnesium is recommended. The same processes that result in osteoporosis also lead to a loss of jaw bone in periodontal diseases. Therefore it seems resaonable to speculate that ipriflavone would be of benefit to those with periodontal disease just as it is for those suffering from osteoporosis.